This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cailleux, A. F. Articles by Schlumberger, M. Search for Related Content PubMed PubMed Citation Articles by Cailleux, A. F. Articles by Schlumberger, M.

Is Diagnostic Iodine-131 Scanning Useful after Total Thyroid Ablation for Differentiated Thyroid Cancer?

Departments of Nuclear Medicine, Surgery, and Physics, Institut Gustave Roussy, 94 805 Villejuif, France

Address correspondence and requests for reprints to: M. Schlumberger, Institut Gustave Roussy and University Paris-Sud, 39, Rue C. Desmoulins, 94 805 Villejuif Cedex, France. E-mail: schlumbg{at}igr.fr

A diagnostic iodine-131 (¹³¹I) total body scan (TBS) is usually recommended 6 to 12 months after thyroid ablation for differentiated thyroid carcinoma. Its usefulness was evaluated in 256 consecutive patients treated and followed up at the Institut Gustave Roussy for papillary (n = 200), well differentiated (n = 27), or poorly differentiated (n = 29) follicular thyroid carcinomas.

All patients underwent a near-total or total thyroidectomy and ¹³¹I ablation with 3.7 GBq (100 mCi). No TBS was performed before ¹³¹I ablation. The TBS performed after the administration of ¹³¹I to destroy the thyroid remnants showed uptake (<2%) limited to the thyroid bed. A diagnostic ¹³¹I-TBS was obtained after withdrawal of T₄ treatment, with either 74 MBq (2 mCi; n = 82) or 185 MBq (5 mCi; n = 174), 6 to 12 months after initial treatment, with serum thyroglobulin (Tg) determination. No interference in the Tg assay was found in these 256 patients.

Uptake in the thyroid bed was not detected (total ablation) in 236 patients, was visible but too low to be measured in 19 patients, and attained 1% in only 1 patient. No uptake was found outside the thyroid bed. The serum Tg level, once thyroid hormone treatment had been withdrawn, was below 1 ng/mL in 210 patients, ranged from 1–10 ng/mL in 31 patients, and was above 10 ng/mL in 15 patients. A ¹³¹I-TBS performed with 3.7 GBq in nine patients with a Tg level above 10 ng/mL, showed foci of uptake outside the thyroid bed in three patients ; lung metastases were demonstrated by a CT scan in another patient, and palpable lymph node metastases were found in one patient.

In conclusion, a diagnostic ¹³¹I-TBS with 74–185 MBq performed 1 yr after thyroid ablation demonstrated no abnormal uptake; it did not correlate with results of Tg determination and only confirmed the completeness of thyroid ablation. The serum Tg level obtained after withdrawal of T₄ treatment permits the selection of patients with a Tg level exceeding 10 ng/mL, for scanning with 3.7 GBq (100 mCi).

This article has been cited by other articles:

				M. G. Castagna, L. Brilli, T. Pilli, A. Montanaro, C. Cipri, C. Fioravanti, F. Sestini, M. Capezzone, and F. Pacini Limited Value of Repeat Recombinant Human Thyrotropin (rhTSH)-Stimulated Thyroglobulin Testing in Differentiated Thyroid Carcinoma Patients with Previous Negative rhTSH-Stimulated Thyroglobulin and Undetectable Basal Serum Thyroglobulin Levels J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 76 - 81. [Abstract] [Full Text] [PDF]

				M. Schlumberger, A. Hitzel, M. E. Toubert, C. Corone, F. Troalen, M. H. Schlageter, F. Claustrat, S. Koscielny, D. Taieb, M. Toubeau, et al. Comparison of Seven Serum Thyroglobulin Assays in the Follow-Up of Papillary and Follicular Thyroid Cancer Patients J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2487 - 2495. [Abstract] [Full Text] [PDF]

				A. Hackshaw, C. Harmer, U. Mallick, M. Haq, and J. A. Franklyn 131I Activity for Remnant Ablation in Patients with Differentiated Thyroid Cancer: A Systematic Review J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 28 - 38. [Abstract] [Full Text] [PDF]

				F. Pacini, M. Schlumberger, H. Dralle, R. Elisei, J. W A Smit, W. Wiersinga, and the European Thyroid Cancer Taskforce European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur. J. Endocrinol., June 1, 2006; 154(6): 787 - 803. [Full Text] [PDF]

				F. Pacini, P. W. Ladenson, M. Schlumberger, A. Driedger, M. Luster, R. T. Kloos, S. Sherman, B. Haugen, C. Corone, E. Molinaro, et al. Radioiodine Ablation of Thyroid Remnants after Preparation with Recombinant Human Thyrotropin in Differentiated Thyroid Carcinoma: Results of an International, Randomized, Controlled Study J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 926 - 932. [Abstract] [Full Text] [PDF]

				M. Torlontano, U. Crocetti, G. Augello, L. D'Aloiso, N. Bonfitto, A. Varraso, F. Dicembrino, S. Modoni, V. Frusciante, A. Di Giorgio, et al. Comparative Evaluation of Recombinant Human Thyrotropin-Stimulated Thyroglobulin Levels, 131I Whole-Body Scintigraphy, and Neck Ultrasonography in the Follow-Up of Patients with Papillary Thyroid Microcarcinoma Who Have Not Undergone Radioiodine Therapy J. Clin. Endocrinol. Metab., January 1, 2006; 91(1): 60 - 63. [Abstract] [Full Text] [PDF]

				F. Pacini, M. Schlumberger, C. Harmer, G. G Berg, O. Cohen, L. Duntas, F. Jamar, B. Jarzab, E. Limbert, P. Lind, et al. Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report Eur. J. Endocrinol., November 1, 2005; 153(5): 651 - 659. [Abstract] [Full Text] [PDF]

				R. T. Kloos and E. L. Mazzaferri A Single Recombinant Human Thyrotropin-Stimulated Serum Thyroglobulin Measurement Predicts Differentiated Thyroid Carcinoma Metastases Three to Five Years Later J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5047 - 5057. [Abstract] [Full Text] [PDF]

				E. L. Mazzaferri Empirically Treating High Serum Thyroglobulin Levels J. Nucl. Med., July 1, 2005; 46(7): 1079 - 1088. [Full Text] [PDF]

				T. Y. Kim, W. B. Kim, E. S. Kim, J. S. Ryu, J. S. Yeo, S. C. Kim, S. J. Hong, and Y. K. Shong Serum Thyroglobulin Levels at the Time of 131I Remnant Ablation Just after Thyroidectomy Are Useful for Early Prediction of Clinical Recurrence in Low-Risk Patients with Differentiated Thyroid Carcinoma J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1440 - 1445. [Abstract] [Full Text] [PDF]

				F. A Verburg, B. de Keizer, C. J M Lips, P. M J Zelissen, and J. M H de Klerk Prognostic significance of successful ablation with radioiodine of differentiated thyroid cancer patients Eur. J. Endocrinol., January 1, 2005; 152(1): 33 - 37. [Abstract] [Full Text] [PDF]

				R. J. Robbins and M. J. Schlumberger The Evolving Role of 131I for the Treatment of Differentiated Thyroid Carcinoma J. Nucl. Med., January 1, 2005; 46(1_suppl): 28S - 37S. [Abstract] [Full Text] [PDF]

				A. Rouxel, G. Hejblum, M.-O. Bernier, P.-Y. Boelle, F. Menegaux, G. Mansour, C. Hoang, A. Aurengo, and L. Leenhardt Prognostic Factors Associated with the Survival of Patients Developing Loco-Regional Recurrences of Differentiated Thyroid Carcinomas J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5362 - 5368. [Abstract] [Full Text] [PDF]

				G. Pellegriti, C. Scollo, G. Lumera, C. Regalbuto, R. Vigneri, and A. Belfiore Clinical Behavior and Outcome of Papillary Thyroid Cancers Smaller than 1.5 cm in Diameter: Study of 299 Cases J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3713 - 3720. [Abstract] [Full Text] [PDF]

				M. Torlontano, M. Attard, U. Crocetti, S. Tumino, R. Bruno, G. Costante, G. D'Azzo, D. Meringolo, E. Ferretti, R. Sacco, et al. Follow-Up of Low Risk Patients with Papillary Thyroid Cancer: Role of Neck Ultrasonography in Detecting Lymph Node Metastases J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3402 - 3407. [Abstract] [Full Text] [PDF]

				M. Toubeau, C. Touzery, P. Arveux, G. Chaplain, G. Vaillant, A. Berriolo, J.-M. Riedinger, C. Boichot, A. Cochet, and F. Brunotte Predictive Value for Disease Progression of Serum Thyroglobulin Levels Measured in the Postoperative Period and After 131I Ablation Therapy in Patients with Differentiated Thyroid Cancer J. Nucl. Med., June 1, 2004; 45(6): 988 - 994. [Abstract] [Full Text] [PDF]

				R. Elisei, A. Vivaldi, L. Agate, E. Molinaro, C. Nencetti, L. Grasso, A. Pinchera, and F. Pacini Low Specificity of Blood Thyroglobulin Messenger Ribonucleic Acid Assay Prevents Its Use in the Follow-Up of Differentiated Thyroid Cancer Patients J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 33 - 39. [Abstract] [Full Text] [PDF]

				J. Modi, A. Patel, R. Terrell, R. M. Tuttle, and G. L. Francis Papillary Thyroid Carcinomas from Young Adults and Children Contain a Mixture of Lymphocytes J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4418 - 4425. [Abstract] [Full Text] [PDF]

				F. Pacini, E. Molinaro, M. G. Castagna, L. Agate, R. Elisei, C. Ceccarelli, F. Lippi, D. Taddei, L. Grasso, and A. Pinchera Recombinant Human Thyrotropin-Stimulated Serum Thyroglobulin Combined with Neck Ultrasonography Has the Highest Sensitivity in Monitoring Differentiated Thyroid Carcinoma J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3668 - 3673. [Abstract] [Full Text] [PDF]

				E. L. Mazzaferri, R. J. Robbins, C. A. Spencer, L. E. Braverman, F. Pacini, L. Wartofsky, B. R. Haugen, S. I. Sherman, D. S. Cooper, G. D. Braunstein, et al. A Consensus Report of the Role of Serum Thyroglobulin as a Monitoring Method for Low-Risk Patients with Papillary Thyroid Carcinoma J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1433 - 1441. [Abstract] [Full Text] [PDF]

				E. Baudin, C. D. Cao, A. F. Cailleux, S. Leboulleux, J. P. Travagli, and M. Schlumberger Positive Predictive Value of Serum Thyroglobulin Levels, Measured during the First Year of Follow-Up after Thyroid Hormone Withdrawal, in Thyroid Cancer Patients J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1107 - 1111. [Abstract] [Full Text] [PDF]

				R. J. Robbins, J. T. Chon, M. Fleisher, S. M. Larson, and R. M. Tuttle Is the Serum Thyroglobulin Response to Recombinant Human Thyrotropin Sufficient, by Itself, to Monitor for Residual Thyroid Carcinoma? J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3242 - 3247. [Abstract] [Full Text] [PDF]

				L. Wartofsky Using Baseline and Recombinant Human TSH-Stimulated Tg Measurements to Manage Thyroid Cancer without Diagnostic 131I Scanning J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1486 - 1489. [Full Text] [PDF]

				E. L. Mazzaferri and R. T. Kloos Is Diagnostic Iodine-131 Scanning with Recombinant Human TSH Useful in the Follow-Up of Differentiated Thyroid Cancer after Thyroid Ablation? J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1490 - 1498. [Abstract] [Full Text] [PDF]

				F. Pacini, M. Capezzone, R. Elisei, C. Ceccarelli, D. Taddei, and A. Pinchera Diagnostic 131-Iodine Whole-Body Scan May Be Avoided in Thyroid Cancer Patients Who Have Undetectable Stimulated Serum Tg Levels After Initial Treatment J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1499 - 1501. [Abstract] [Full Text] [PDF]

				F. Pacini, E. Molinaro, F. Lippi, M. G. Castagna, L. Agate, C. Ceccarelli, D. Taddei, R. Elisei, M. Capezzone, and A. Pinchera Prediction of Disease Status by Recombinant Human TSH-Stimulated Serum Tg in the Postsurgical Follow-Up of Differentiated Thyroid Carcinoma J. Clin. Endocrinol. Metab., December 1, 2001; 86(12): 5686 - 5690. [Abstract] [Full Text] [PDF]

				F. Pacini, L. Agate, R. Elisei, M. Capezzone, C. Ceccarelli, F. Lippi, E. Molinaro, and A. Pinchera Outcome of Differentiated Thyroid Cancer with Detectable Serum Tg and Negative Diagnostic 131I Whole Body Scan: Comparison of Patients Treated with High 131I Activities Versus Untreated Patients J. Clin. Endocrinol. Metab., September 1, 2001; 86(9): 4092 - 4097. [Abstract] [Full Text] [PDF]

				E. L. Mazzaferri and R. T. Kloos Current Approaches to Primary Therapy for Papillary and Follicular Thyroid Cancer J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1447 - 1463. [Full Text]

				R. J. Robbins, R. M. Tuttle, R. N. Sharaf, S. M. Larson, H. K. Robbins, R. A. Ghossein, A. Smith, and W. D. Drucker Preparation by Recombinant Human Thyrotropin or Thyroid Hormone Withdrawal Are Comparable for the Detection of Residual Differentiated Thyroid Carcinoma J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 619 - 625. [Abstract] [Full Text]

				S. A. R. Doi Usefulness of the Diagnostic Total Body Scan in Differentiated Thyroid Cancer J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 949 - 949. [Full Text]